Review




Structured Review

Mabtech Inc human il-4 elispot pro kit (alp)
Immunogenicity of prototype-Beta chimeric vaccine in rhesus macaques Twenty-four rhesus macaques (see <xref ref-type=Table S1 ) were immunized with 3 doses of prototype-Beta chimeric RBD-dimer vaccine or sham (n = 12), 21 days apart. Serum samples were collected according to the study schedule shown in Figure S5 B. (A) Endpoint titer of antigen-binding IgG. (B) 50% neutralization titer of pseudotyped virus (prototype, Alpha, Beta, Delta, and Omicron) in serum. (C) 50% neutralization titer of authentic SARS-CoV-2 (prototype, Alpha, Beta, and Delta). (D) 50% neutralization titer of authentic SARS-CoV-2 (prototype, Beta and Omicron). The values shown in (A)–(D) are the GMT ± 95% confidence interval (CI). (E) Summed IFN-γ, IL-2 and IL-4 ELISPOT responses in PBMCs collected at day 6 after the third dose toward peptides spanning SARS-CoV-2 RBD. The values are means ± SEM. p values were analyzed with two-tailed Mann-Whitney test. ( ∗∗ p < 0.01; ∗∗∗ p <0.001; ∗∗∗∗ p < 0.0001). " width="250" height="auto" />
Human Il 4 Elispot Pro Kit (Alp), supplied by Mabtech Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+il-4+elispot+pro+kit+(alp)/elispot+kit/pmc09042943-54-0-7
Average 90 stars, based on 1 article reviews
human il-4 elispot pro kit (alp) - by Bioz Stars, 2026-09
90/100 stars

Images

1) Product Images from "Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2"

Article Title: Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2

Journal: Cell

doi: 10.1016/j.cell.2022.04.029

Immunogenicity of prototype-Beta chimeric vaccine in rhesus macaques Twenty-four rhesus macaques (see <xref ref-type=Table S1 ) were immunized with 3 doses of prototype-Beta chimeric RBD-dimer vaccine or sham (n = 12), 21 days apart. Serum samples were collected according to the study schedule shown in Figure S5 B. (A) Endpoint titer of antigen-binding IgG. (B) 50% neutralization titer of pseudotyped virus (prototype, Alpha, Beta, Delta, and Omicron) in serum. (C) 50% neutralization titer of authentic SARS-CoV-2 (prototype, Alpha, Beta, and Delta). (D) 50% neutralization titer of authentic SARS-CoV-2 (prototype, Beta and Omicron). The values shown in (A)–(D) are the GMT ± 95% confidence interval (CI). (E) Summed IFN-γ, IL-2 and IL-4 ELISPOT responses in PBMCs collected at day 6 after the third dose toward peptides spanning SARS-CoV-2 RBD. The values are means ± SEM. p values were analyzed with two-tailed Mann-Whitney test. ( ∗∗ p < 0.01; ∗∗∗ p <0.001; ∗∗∗∗ p < 0.0001). " title="... interval (CI). (E) Summed IFN-γ, IL-2 and IL-4 ELISPOT responses in PBMCs collected at day 6 after ..." property="contentUrl" width="100%" height="100%"/>
Figure Legend Snippet: Immunogenicity of prototype-Beta chimeric vaccine in rhesus macaques Twenty-four rhesus macaques (see Table S1 ) were immunized with 3 doses of prototype-Beta chimeric RBD-dimer vaccine or sham (n = 12), 21 days apart. Serum samples were collected according to the study schedule shown in Figure S5 B. (A) Endpoint titer of antigen-binding IgG. (B) 50% neutralization titer of pseudotyped virus (prototype, Alpha, Beta, Delta, and Omicron) in serum. (C) 50% neutralization titer of authentic SARS-CoV-2 (prototype, Alpha, Beta, and Delta). (D) 50% neutralization titer of authentic SARS-CoV-2 (prototype, Beta and Omicron). The values shown in (A)–(D) are the GMT ± 95% confidence interval (CI). (E) Summed IFN-γ, IL-2 and IL-4 ELISPOT responses in PBMCs collected at day 6 after the third dose toward peptides spanning SARS-CoV-2 RBD. The values are means ± SEM. p values were analyzed with two-tailed Mann-Whitney test. ( ∗∗ p < 0.01; ∗∗∗ p <0.001; ∗∗∗∗ p < 0.0001).

Techniques Used: Immunopeptidomics, Binding Assay, Neutralization, Virus, Enzyme-linked Immunospot, Two Tailed Test, MANN-WHITNEY


Figure Legend Snippet:

Techniques Used: Virus, Isolation, Infection, Variant Assay, Recombinant, Adjuvant, Enzyme-linked Immunospot, Software, Microscopy

Related Articles

Enzyme-linked Immunospot:

Article Title: Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2
Article Snippet: Human IL-4 ELISpot PRO kit (ALP) , MabTech , Cat3410-2APW-10.

Immunopeptidomics:

Article Title: Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2
Article Snippet: Human IL-4 ELISpot PRO kit (ALP) , MabTech , Cat3410-2APW-10.

Binding Assay:

Article Title: Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2
Article Snippet: Human IL-4 ELISpot PRO kit (ALP) , MabTech , Cat3410-2APW-10.

Neutralization:

Article Title: Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2
Article Snippet: Human IL-4 ELISpot PRO kit (ALP) , MabTech , Cat3410-2APW-10.

Virus:

Article Title: Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2
Article Snippet: Human IL-4 ELISpot PRO kit (ALP) , MabTech , Cat3410-2APW-10.

Two Tailed Test:

Article Title: Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2
Article Snippet: Human IL-4 ELISpot PRO kit (ALP) , MabTech , Cat3410-2APW-10.

MANN-WHITNEY:

Article Title: Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2
Article Snippet: Human IL-4 ELISpot PRO kit (ALP) , MabTech , Cat3410-2APW-10.

Isolation:

Article Title: Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2
Article Snippet: Human IL-4 ELISpot PRO kit (ALP) , MabTech , Cat3410-2APW-10.

Infection:

Article Title: Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2
Article Snippet: Human IL-4 ELISpot PRO kit (ALP) , MabTech , Cat3410-2APW-10.

Variant Assay:

Article Title: Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2
Article Snippet: Human IL-4 ELISpot PRO kit (ALP) , MabTech , Cat3410-2APW-10.

Recombinant:

Article Title: Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2
Article Snippet: Human IL-4 ELISpot PRO kit (ALP) , MabTech , Cat3410-2APW-10.

Adjuvant:

Article Title: Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2
Article Snippet: Human IL-4 ELISpot PRO kit (ALP) , MabTech , Cat3410-2APW-10.

Software:

Article Title: Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2
Article Snippet: Human IL-4 ELISpot PRO kit (ALP) , MabTech , Cat3410-2APW-10.

Microscopy:

Article Title: Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2
Article Snippet: Human IL-4 ELISpot PRO kit (ALP) , MabTech , Cat3410-2APW-10.



Similar Products


Image Search Results


Immunogenicity of prototype-Beta chimeric vaccine in rhesus macaques Twenty-four rhesus macaques (see <xref ref-type=Table S1 ) were immunized with 3 doses of prototype-Beta chimeric RBD-dimer vaccine or sham (n = 12), 21 days apart. Serum samples were collected according to the study schedule shown in Figure S5 B. (A) Endpoint titer of antigen-binding IgG. (B) 50% neutralization titer of pseudotyped virus (prototype, Alpha, Beta, Delta, and Omicron) in serum. (C) 50% neutralization titer of authentic SARS-CoV-2 (prototype, Alpha, Beta, and Delta). (D) 50% neutralization titer of authentic SARS-CoV-2 (prototype, Beta and Omicron). The values shown in (A)–(D) are the GMT ± 95% confidence interval (CI). (E) Summed IFN-γ, IL-2 and IL-4 ELISPOT responses in PBMCs collected at day 6 after the third dose toward peptides spanning SARS-CoV-2 RBD. The values are means ± SEM. p values were analyzed with two-tailed Mann-Whitney test. ( ∗∗ p < 0.01; ∗∗∗ p <0.001; ∗∗∗∗ p < 0.0001). " width="100%" height="100%">

Journal: Cell

Article Title: Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2

doi: 10.1016/j.cell.2022.04.029

Figure Lengend Snippet: Immunogenicity of prototype-Beta chimeric vaccine in rhesus macaques Twenty-four rhesus macaques (see Table S1 ) were immunized with 3 doses of prototype-Beta chimeric RBD-dimer vaccine or sham (n = 12), 21 days apart. Serum samples were collected according to the study schedule shown in Figure S5 B. (A) Endpoint titer of antigen-binding IgG. (B) 50% neutralization titer of pseudotyped virus (prototype, Alpha, Beta, Delta, and Omicron) in serum. (C) 50% neutralization titer of authentic SARS-CoV-2 (prototype, Alpha, Beta, and Delta). (D) 50% neutralization titer of authentic SARS-CoV-2 (prototype, Beta and Omicron). The values shown in (A)–(D) are the GMT ± 95% confidence interval (CI). (E) Summed IFN-γ, IL-2 and IL-4 ELISPOT responses in PBMCs collected at day 6 after the third dose toward peptides spanning SARS-CoV-2 RBD. The values are means ± SEM. p values were analyzed with two-tailed Mann-Whitney test. ( ∗∗ p < 0.01; ∗∗∗ p <0.001; ∗∗∗∗ p < 0.0001).

Article Snippet: Human IL-4 ELISpot PRO kit (ALP) , MabTech , Cat#3410-2APW-10.

Techniques: Immunopeptidomics, Binding Assay, Neutralization, Virus, Enzyme-linked Immunospot, Two Tailed Test, MANN-WHITNEY

Journal: Cell

Article Title: Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2

doi: 10.1016/j.cell.2022.04.029

Figure Lengend Snippet:

Article Snippet: Human IL-4 ELISpot PRO kit (ALP) , MabTech , Cat#3410-2APW-10.

Techniques: Virus, Isolation, Infection, Variant Assay, Recombinant, Adjuvant, Enzyme-linked Immunospot, Software, Microscopy